These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785 [TBL] [Abstract][Full Text] [Related]
23. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study. Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913 [TBL] [Abstract][Full Text] [Related]
24. Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins. Ylikorkala O; Kuusi T; Tikkanen MJ; Viinikka L J Clin Endocrinol Metab; 1987 Dec; 65(6):1238-42. PubMed ID: 2960690 [TBL] [Abstract][Full Text] [Related]
25. The role of triphasic levonorgestrel in oral contraception: a review of metabolic and hemostatic effects. Lachnit-Fixson U Gynecol Endocrinol; 1996 Jun; 10(3):207-18. PubMed ID: 8862497 [TBL] [Abstract][Full Text] [Related]
26. Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel. Basdevant A; Conard J; Pelissier C; Guyene TT; Lapousterle C; Mayer M; Guy-Grand B; Degrelle H Contraception; 1993 Sep; 48(3):193-204. PubMed ID: 8222650 [TBL] [Abstract][Full Text] [Related]
27. Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives. Oyelola OO Contraception; 1993 May; 47(5):445-54. PubMed ID: 8513671 [TBL] [Abstract][Full Text] [Related]
28. Comparative effects of monophasic desogestrel plus ethinyloestradiol and triphasic levonorgestrel plus ethinyloestradiol on lipid metabolism. Kloosterboer HJ; van Wayjen RG; van den Ende A Contraception; 1986 Aug; 34(2):135-44. PubMed ID: 2946552 [TBL] [Abstract][Full Text] [Related]
29. Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives. Kuhl H; März W; Jung-Hoffmann C; Heidt F; Gross W Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):363-9. PubMed ID: 2142576 [TBL] [Abstract][Full Text] [Related]
30. Plasma lipoproteins and fatty acid composition after "minipill". Sassolas A; Lagarde M; Guichardant M; Quincy C; Dechavanne M Contraception; 1983 Oct; 28(4):357-68. PubMed ID: 6421540 [TBL] [Abstract][Full Text] [Related]
31. Contraception in older woman. Volpe A; Silferi M; Genazzani AD; Genazzani AR Contraception; 1993 Mar; 47(3):229-39. PubMed ID: 8462314 [TBL] [Abstract][Full Text] [Related]
32. Effects of desogestrel and levonorgestrel in low-dose oestrogen oral contraceptives on serum lipoproteins. Bergink EW; Borglin NE; Klottrup P; Liukko P Contraception; 1982 May; 25(5):477-85. PubMed ID: 6213374 [No Abstract] [Full Text] [Related]
33. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study. Lipson A; Stoy DB; LaRosa JC; Muesing RA; Cleary PA; Miller VT; Gilbert PR; Stadel B Contraception; 1986 Aug; 34(2):121-34. PubMed ID: 3096633 [TBL] [Abstract][Full Text] [Related]
34. Two oral contraceptives, efficacy, serum proteins, and lipid metabolism. A comparative multicentre study on a triphasic and a fixed dose combination. Cullberg G; Samsioe G; Andersen RF; Bredesgaard P; Andersen NB; Ernerot H; Fanøe E; Fylling P; Haack-Sørensen PE; Klottrup P; Pedersen JH; Sandager T Contraception; 1982 Sep; 26(3):229-43. PubMed ID: 6217028 [TBL] [Abstract][Full Text] [Related]
35. The effect of triphasic and biphasic oral contraceptive preparations on HDL-cholesterol and LDL-cholesterol in young women. Percival-Smith RK; Morrison BJ; Sizto R; Abercrombie B Contraception; 1987 Feb; 35(2):179-87. PubMed ID: 3595143 [TBL] [Abstract][Full Text] [Related]
36. Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: a controlled, comparative, 12-month clinical trial. Notelovitz M; Feldman EB; Gillespy M; Gudat J Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1269-80. PubMed ID: 2655452 [TBL] [Abstract][Full Text] [Related]
37. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome. Falsetti L; Pasinetti E Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434 [TBL] [Abstract][Full Text] [Related]
38. Lipid metabolic studies in women with a polycystic ovary syndrome during treatment with a low-dose desogestrel-ethinylestradiol combination. Cullberg G; Hamberger L; Mattsson LA; Mobacken H; Samsioe G Acta Obstet Gynecol Scand; 1985; 64(3):203-7. PubMed ID: 3160212 [TBL] [Abstract][Full Text] [Related]
39. A comparison of the effects of two triphasic oral contraceptives on haemostasis. Cohen H; Mackie IJ; Walshe K; Gillmer MD; Machin SJ Br J Haematol; 1988 Jun; 69(2):259-63. PubMed ID: 3390394 [TBL] [Abstract][Full Text] [Related]